Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Src signaling was considered a potential mechanism of resistance to androgen-targeted therapy. In a randomized trial, we studied whether the addition of dasatinib would delay prostate cancer progression compared with abiraterone alone. Progression-free survival was not prolonged, although there were...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Genitourin Cancer
Autors principals: Dorff, Tanya B., Quinn, David I., Pinski, Jacek K., Goldkorn, Amir, Sadeghi, Sarmad, Tsao-Wei, Denice, Groshen, Susan, Kuhn, Peter, Gross, Mitchell E.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446934/
https://ncbi.nlm.nih.gov/pubmed/31227432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.02.010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars